Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II/III development across risk settings.
Phase I Clinical Results
Cohort
Primary Endpoint
Key Efficacy Results
Durability
Intermediate-Risk NMIBC
Safety (met)
89% complete response rate
Median duration of CR: 18 months
High-Risk NMIBC
Safety (met)
Median recurrence-free survival: 20 months
12-month RFS rate: 83%
Overall
Safety + encouraging efficacy
Prolonged responses over time
Supports Phase II/III advancement
Study Design:
Population: Intermediate-risk and high-risk NMIBC with select FGFR alterations
Treatment: Intravesical erdafitinib-releasing system (Erda-iDRS)
Registrational study vs. standard of care (BCG or chemotherapy)
Regulatory Strategy
2028-2029
NDA filing for FGFR+ NMIBC; potential breakthrough therapy designation
Companion Diagnostic
2026-2027
FGFR alteration detection (FISH or NGS) for patient selection
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase II/III development, FGFR biomarker validation, and competitive positioning for Erda-iDRS in non-muscle-invasive bladder cancer. Actual results may differ due to intravesical delivery technical challenges, FGFR testing adoption, and competitive dynamics with BCG and immunotherapy.-Fineline Info & Tech
By Fineline Cube